Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 9:30 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2713–2736 of 26,682 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Placenta Accreta
Interventions: Conservative management for placenta accreta spectrum (PAS), Cesarean hysterectomy for placenta accreta spectrum (PAS); Procedure
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Stroke, Acute
Interventions: Trans-Sodium Crocetinate, Placebo; Drug · Other
Lead sponsor: Diffusion Pharmaceuticals Inc; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Los Angeles, California • Charlottesville, Virginia

Conditions: Dry Eye Disease
Interventions: NOV03, Saline Solution; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 620 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 35
States / cities: Phoenix, Arizona • Garden Grove, California • Hemet, California + 29 more

Conditions: Non Infectious Uveitis
Interventions: DE-109 Intravitreal Injections, Sham Procedure, DE-109 Intravitreal Injections (Open Label); Drug · Other
Lead sponsor: Santen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 38
States / cities: Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 32 more

Conditions: Alcohol Abuse, Posttraumatic Stress Disorder
Interventions: Prazosin, Placebo medication; Drug
Lead sponsor: Seattle Institute for Biomedical and Clinical Research; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Normal Healthy Volunteers
Interventions: Oral methylnaltrexone, Oral placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 1
States / cities: Tarrytown, New York

Conditions: Ileus
Interventions: Alvimopan; Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: Exton, Pennsylvania

Conditions: Borderline Personality Disorder
Interventions: BI 1358894, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 16
States / cities: Anaheim, California • Temecula, California • Upland, California + 13 more

Conditions: Colonic Neoplasms
Interventions: Normal (0.9%) saline, HalfLytely; Drug
Lead sponsor: Arya, Vijaypal, M.D., P.C.; Individual
Eligibility: 21 Years to 70 Years
Enrollment: 133 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Middle Village, New York

Conditions: Nasopharyngeal Carcinoma
Interventions: Spartalizumab, Investigator choice of chemotherapy; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 4
States / cities: Marietta, Georgia • Detroit, Michigan • New York, New York + 1 more

Conditions: Traumatic Brain Injury
Interventions: SB623 cells, Sham Control; Biological · Procedure
Lead sponsor: SanBio, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 25
States / cities: Los Angeles, California • Oceanside, California • Orange, California + 16 more

Conditions: PTSD, Alcohol Abuse, Alcoholism
Interventions: Topiramate, Placebo administration; Drug · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Head and Neck Cancer, Mucositis, Pain, Radiation Toxicity
Interventions: palifermin, cisplatin, placebo, neck dissection, radiation therapy; Biological · Drug · Other + 2 more
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 47
States / cities: Scottsdale, Arizona • Auburn, California • Burbank, California + 40 more

Conditions: Prostate Cancer
Interventions: Exercise and Diet; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Male only
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Overweight, Obesity
Interventions: 500 mL/day of a beverage providing approximately 625 mg catechins, Control beverage matched for energy and caffeine content; Dietary Supplement · Other
Lead sponsor: Provident Clinical Research; Other
Eligibility: 21 Years to 65 Years
Enrollment: 132 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 2
States / cities: St. Petersburg, Florida • Bloomington, Indiana

Conditions: Nephrolithiasis
Interventions: Fexofenadine Hcl 180Mg Tab, Placebo; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Safety Issues
Interventions: Placebo, PH100 100mg, PH100 200mg, PH100 400mg, PH100 800mg, PH100 1200mg, PH100 1600mg; Drug
Lead sponsor: Phloronol Inc.; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: ADHD, Anxiety, Generalized Anxiety, Social Anxiety Disorder
Interventions: Centanafadine, Placebo; Drug · Other
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 46
States / cities: Dothan, Alabama • Little Rock, Arkansas • Rogers, Arkansas + 41 more

Conditions: Recurrent Clostridium Difficile Infection
Interventions: Lactobacillus acidophilus CL1285® and Lactobacillus casei, Placebo; Dietary Supplement
Lead sponsor: Bio-K Plus International Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: New Hyde Park, New York

Conditions: Advanced Solid Tumor, Pain
Interventions: Meaning-Centered Pain Coping Skills Training; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 211 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Anemia
Interventions: Epoetin Alfa; Drug
Lead sponsor: Mehrotra, Anita, M.D.; Individual
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Overactive Bladder (OAB)
Interventions: NT 201 200U and Vibe System, NT 201 300U and Vibe System, Placebo and sham; Combination Product
Lead sponsor: Vensica Therapeutics Ltd.; Industry
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Margate, Florida • Pompano Beach, Florida • Reno, Nevada

Conditions: Smoking Cessation
Interventions: Quitxt text messaging or Chat, Usual care; Behavioral · Other
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 29 Years
Enrollment: 1,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Acute Heart Failure, Acute Decompensation of Chronic Heart Failure, New Onset of Heart Failure
Interventions: tezosentan; Drug
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 735 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 8
States / cities: Birmingham, Alabama • Palo Alto, California • Denver, Colorado + 5 more

Search by objective public record fields.

Conservative Management for PAS Pilot

Efficacy and Safety of Trans Sodium Crocetinate (TSC) for Treatment of Suspected Stroke

Effect of NOV03 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Mojave Study)

LUMINA Phase III Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 Sirolimus for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye

Prazosin for Alcohol Dependence and Posttraumatic Stress Disorder

Tolerance and Pharmacokinetics Study of MNTX Tablets

Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus

A Study to Test Different Doses of BI 1358894 and Find Out Whether They Reduce Symptoms in People With Borderline Personality Disorder

Yoga and Bolus Lukewarm Saline as Rapid Colonoscopy Preparation

Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

A Study of Modified Stem Cells in Traumatic Brain Injury (TBI)

Topiramate Treatment of Alcohol Use Disorders in Veterans With Post Traumatic Stress Disorder (PTSD): A Pilot Controlled Trial of Augmentation Therapy

Palifermin in Lessening Oral Mucositis in Patients Undergoing Radiation Therapy and Chemotherapy for Locally Advanced Head and Neck Cancer

Diet and Exercise Interventions Among Men With Prostate Cancer (Prostate 8-II)

Efficacy of a Tea Catechin Sports Drink for Enhancing Exercise-Induced Fat Loss

Effect of Antihistamines on Ureteral Stent-Related Symptoms

Phase I Study of PH100 (Ecklonia Cava Phlorotannins)

P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety

BIO-K+ CL1285 for Prevention of Recurrent Clostridium Difficile Infection

Meaning-Centered Pain Coping Skills Training for Cancer Pain

Study of Epoetin Alfa to Treat Anemia After Kidney Transplantation

RELIEVE Study: NT 201 Intravesical Administration Using Vibe System (ViXe Combination Product) for the Treatment of Idiopathic Overactive Bladder

Quitxt Mobile Text Messaging Cessation Research Study

Tezosentan in Acute Heart Failure